VYNE Therapeutics Inc. Net Income Loss

• VYNE Therapeutics Inc. showed an increase of +33.5% in Net Income Loss from 2024 to 2025.
• This data is from VYNE Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: -$2.27 million | Q2 2016: -$3.56 million | Q3 2016: -$3.40 million | Q4 2016: -$4.84 million | Q1 2017: -$5.47 million | Q2 2017: -$6.15 million | Q3 2017: -$8.17 million | Q4 2017: -$9.28 million | Q1 2018: -$12.66 million | Q2 2018: -$8.35 million | Q3 2018: -$12.85 million | Q4 2018: -$17.59 million | Q1 2019: -$15.20 million | Q2 2019: -$18.99 million | Q3 2019: -$23.16 million | Q4 2019: -$21.50 million | Q1 2020: -$40.23 million | Q2 2020: -$167.44 million | Q3 2020: -$24.71 million | Q1 2021: -$20.55 million | Q2 2021: -$19.92 million | Q3 2021: -$21.29 million | Q1 2022: $4.67 million | Q2 2022: -$8.48 million | Q3 2022: -$9.46 million | Q1 2023: -$5.62 million | Q2 2023: -$10.06 million | Q3 2023: -$6.58 million | Q1 2024: -$6.25 million | Q2 2024: -$9.41 million | Q3 2024: -$12.16 million | Q1 2025: -$8.61 million | Q2 2025: -$5.76 million.
• Over the full 11 years of available data (2015 to 2025), VYNE Therapeutics Inc.'s Net Income Loss has declined by 474.7%.
• Historical annual values: Fiscal year 2025: -$26.48 million | Fiscal year 2024: -$39.83 million | Fiscal year 2023: -$28.45 million | Fiscal year 2022: -$23.21 million | Fiscal year 2021: -$73.33 million | Fiscal year 2020: -$255.57 million | Fiscal year 2019: -$95.18 million | Fiscal year 2018: -$74.16 million | Fiscal year 2017: -$29.08 million | Fiscal year 2016: -$14.07 million | Fiscal year 2015: -$4.61 million.
• Data sourced from SEC EDGAR public filings as of August 9, 2026.

Last verified: August 9, 2026